WO2002039832A1 - Use of lactitol for improving intestinal microflora - Google Patents
Use of lactitol for improving intestinal microflora Download PDFInfo
- Publication number
- WO2002039832A1 WO2002039832A1 PCT/NL2000/000843 NL0000843W WO0239832A1 WO 2002039832 A1 WO2002039832 A1 WO 2002039832A1 NL 0000843 W NL0000843 W NL 0000843W WO 0239832 A1 WO0239832 A1 WO 0239832A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactitol
- preparation
- use according
- improving intestinal
- amount
- Prior art date
Links
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 title claims abstract description 19
- 229960003451 lactitol Drugs 0.000 title claims abstract description 19
- 235000010448 lactitol Nutrition 0.000 title claims abstract description 19
- 239000000832 lactitol Substances 0.000 title claims abstract description 19
- 244000005709 gut microbiome Species 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 8
- 235000016709 nutrition Nutrition 0.000 claims abstract description 8
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 3
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 3
- 206010022678 Intestinal infections Diseases 0.000 claims abstract description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 3
- 230000002708 enhancing effect Effects 0.000 claims abstract description 3
- 230000036039 immunity Effects 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 230000007413 intestinal health Effects 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000002354 daily effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- lactitol for improving intestinal microfiora
- the present invention relates to a preparation for improving intestinal microfiora, in particular a nutritional preparation such as a food supplement containing the active substance or a food product supplemented with the active substance.
- probiotics are used for instance as food supplement.
- Probiotics are preparations containing beneficial bacteria and yeasts such as Lactobacillus. A similar effect can be obtained using "prebiotics”.
- Prebiotics are nondigestible food ingredients that stimulate the growth and activity of "friendly" bacteria already present in the intestine.
- lactitol can be used as a prebiotic in a formulated food product or supplement.
- the present invention provides for the use of lactitol in the preparation of a nutritional preparation for improving intestinal microfiora.
- lactitol only the effect of a daily dose of 20 g lactitol and higher was tested for the treatment of specific diseases like hepatic encephalopathy.
- the nutritional preparation of the invention preferably contains 5 to 15 g lactitol per daily dose. It has been found that an amount lower than 5 g per daily dose does not result in a beneficial effect. An amount above 15 g lactitol per daily dose is difficult to process in a portion size of a food product.
- the preparation contains 7.5 to 12.5 g lactitol per daily dose, in particular 10 g.
- the preparation according to the invention is used to improve intestinal microfiora, in particular intestinal health in general. It has been shown that this preparation can increase the amount of healthy bacteria, in particular Lactobacilli and Bifidobacteria.
- the preparation is preferably administered to healthy humans and can be used for the prevention of intestinal infections, colon cancer, diarrhea or in enhancing immunity.
- the preparation of the invention can be a food supplement, a food product or a complete food.
- the lactitol can be administrated as such, for instance in a tablet or powder.
- Other beneficial components can be added to the food supplement or food such as vitamins and minerals.
- the food product of the invention can be a conventional food product to which the lactitol has been added.
- Examples of such products are candy bars, candy, dairy products, bakery products, etc.
- lactitol in a food product improves the gut microfiora of healthy people
- 10 g of lactitol was administered to 25 healthy subjects every day for a week.
- the lactitol was administered in a chocolate bar.
- a sugar containing chocolate bar was administered to another group of 25 persons.
- the test was performed as a double blind randomized test.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to the use of lactitol in the preparation of a nutritional preparation for improving intestinal microflora, in particular in an amount of 5 to 15 g lactitol per daily dose. The nutritional preparation can be a food supplement or a food product. It is particularly beneficial in the prevention of intestinal infections, colon cancer, diarrhoea or in enhancing immunity.
Description
Use of lactitol for improving intestinal microfiora
The present invention relates to a preparation for improving intestinal microfiora, in particular a nutritional preparation such as a food supplement containing the active substance or a food product supplemented with the active substance.
It has been suggested for some time that a healthy intestinal microfiora can have a beneficial effect on the overall health of humans. To improve the intestinal microfiora "probiotics" are used for instance as food supplement. Probiotics are preparations containing beneficial bacteria and yeasts such as Lactobacillus. A similar effect can be obtained using "prebiotics". Prebiotics are nondigestible food ingredients that stimulate the growth and activity of "friendly" bacteria already present in the intestine.
It has now been found that lactitol can be used as a prebiotic in a formulated food product or supplement. The present invention provides for the use of lactitol in the preparation of a nutritional preparation for improving intestinal microfiora. Until now, only the effect of a daily dose of 20 g lactitol and higher was tested for the treatment of specific diseases like hepatic encephalopathy.
The nutritional preparation of the invention preferably contains 5 to 15 g lactitol per daily dose. It has been found that an amount lower than 5 g per daily dose does not result in a beneficial effect. An amount above 15 g lactitol per daily dose is difficult to process in a portion size of a food product. Preferably the preparation contains 7.5 to 12.5 g lactitol per daily dose, in particular 10 g.
The preparation according to the invention is used to improve intestinal microfiora, in particular intestinal health in general. It has been shown that this preparation can increase the amount of healthy bacteria, in particular Lactobacilli and Bifidobacteria.
The preparation is preferably administered to healthy humans and can be used for the prevention of intestinal infections, colon cancer, diarrhea or in enhancing immunity.
The preparation of the invention can be a food supplement, a food product or a complete food. In a food supplement the lactitol can be administrated as such, for instance in a tablet or powder. Other beneficial components can be added to the food supplement or food such as vitamins and minerals.
The food product of the invention can be a conventional food product to which the lactitol has been added. Examples of such products are candy bars, candy, dairy products, bakery products, etc.
Example
To test if lactitol in a food product improves the gut microfiora of healthy people, 10 g of lactitol was administered to 25 healthy subjects every day for a week. The lactitol was administered in a chocolate bar. As a placebo, a sugar containing chocolate bar was administered to another group of 25 persons. The test was performed as a double blind randomized test.
From the test persons faeces were collected on day 0 and 7. In these faeces the amount of different bacteria was counted, see Table 1. It was significantly proven that 10 g lactitol a day increased the amount of bifidobacteria in the colon. The increase in the amount of bifidobacteria has been defined as a prebiotic effect.
Table 1
Claims
1. Use of lactitol in the preparation of a nutritional preparation for improving intestinal microfiora.
2. Use according to claim 1, in an amount of 5 to 15 g lactitol per daily dose.
3. Use according to claim 2, in an amount of 7.5 to 12.5 g lactitol per daily dose.
4. Use according to any of claims 1 to 3 for improving intestinal health.
5. Use according to any of the preceding claims, wherein the nutritional preparation is a food supplement.
6. Use according to any of claims 1 to 4, wherein the nutritional preparation is a food product.
7. Use according to any of the preceding claims in the prevention of intestinal infections, colon cancer, diarrhea or in enhancing immunity.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2000/000843 WO2002039832A1 (en) | 2000-11-17 | 2000-11-17 | Use of lactitol for improving intestinal microflora |
| AU2001222369A AU2001222369A1 (en) | 2000-11-17 | 2000-11-17 | Use of lactitol for improving intestinal microflora |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2000/000843 WO2002039832A1 (en) | 2000-11-17 | 2000-11-17 | Use of lactitol for improving intestinal microflora |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002039832A1 true WO2002039832A1 (en) | 2002-05-23 |
Family
ID=19760723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/NL2000/000843 WO2002039832A1 (en) | 2000-11-17 | 2000-11-17 | Use of lactitol for improving intestinal microflora |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001222369A1 (en) |
| WO (1) | WO2002039832A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004026316A1 (en) * | 2002-09-17 | 2004-04-01 | Danisco A/S | Novel use of carbohydrates and compositions |
| CN111936148A (en) * | 2018-04-03 | 2020-11-13 | 瓦伦塔有限责任公司 | Lactitol for non-alcoholic fatty liver disease and oral pharmaceutical dosage form |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3957976A (en) * | 1972-09-29 | 1976-05-18 | Kabushiki-Kaisha Hayashibara Seibutsukagaku Kenkyujo | Methods for reducing cholesterol levels |
| GB2113998A (en) * | 1982-02-05 | 1983-08-17 | Cv Chemie Combinatie Amsterdam | Lactitol for the treatment of liver disease |
| US4760055A (en) * | 1985-08-08 | 1988-07-26 | Valio Meijerien Keskusosuusliike | Growth-stimulating animal feed, a process for preparing it, and an additive to be used in it |
| EP0464362A1 (en) * | 1990-06-27 | 1992-01-08 | Valio Meijerien Keskusosuusliike | Feed for promoting the growth and intestinal function of animals |
| US5651988A (en) * | 1995-08-18 | 1997-07-29 | Xyrofin Oy | Combination osmotic and bulk forming laxatives |
| US5672589A (en) * | 1988-12-01 | 1997-09-30 | Suomen Xyrofin Oy | Crystalline lactitol monohydrate and a process for the preparation thereof, use thereof, and sweetening agent |
-
2000
- 2000-11-17 WO PCT/NL2000/000843 patent/WO2002039832A1/en not_active Application Discontinuation
- 2000-11-17 AU AU2001222369A patent/AU2001222369A1/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3957976A (en) * | 1972-09-29 | 1976-05-18 | Kabushiki-Kaisha Hayashibara Seibutsukagaku Kenkyujo | Methods for reducing cholesterol levels |
| GB2113998A (en) * | 1982-02-05 | 1983-08-17 | Cv Chemie Combinatie Amsterdam | Lactitol for the treatment of liver disease |
| US4760055A (en) * | 1985-08-08 | 1988-07-26 | Valio Meijerien Keskusosuusliike | Growth-stimulating animal feed, a process for preparing it, and an additive to be used in it |
| US5672589A (en) * | 1988-12-01 | 1997-09-30 | Suomen Xyrofin Oy | Crystalline lactitol monohydrate and a process for the preparation thereof, use thereof, and sweetening agent |
| EP0464362A1 (en) * | 1990-06-27 | 1992-01-08 | Valio Meijerien Keskusosuusliike | Feed for promoting the growth and intestinal function of animals |
| US5651988A (en) * | 1995-08-18 | 1997-07-29 | Xyrofin Oy | Combination osmotic and bulk forming laxatives |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004026316A1 (en) * | 2002-09-17 | 2004-04-01 | Danisco A/S | Novel use of carbohydrates and compositions |
| CN111936148A (en) * | 2018-04-03 | 2020-11-13 | 瓦伦塔有限责任公司 | Lactitol for non-alcoholic fatty liver disease and oral pharmaceutical dosage form |
| CN111936148B (en) * | 2018-04-03 | 2023-07-14 | 瓦伦塔有限责任公司 | Lactitol and oral pharmaceutical dosage form for non-alcoholic fatty liver disease |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001222369A1 (en) | 2002-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5558475B2 (en) | Elderberry extract and L. Paracasei, L. Casei, L. Bulgarix or S. Composition comprising a combination with a strain of Thermophilus | |
| CN100512667C (en) | Pig feed addictive | |
| CN100553474C (en) | A kind of chicken feed addictive | |
| CN100553473C (en) | A kind of sheep feed additive | |
| EP3248475A1 (en) | Composition | |
| DE202010008308U1 (en) | Composition for nutritive supplementation or treatment for urinary tract infections and / or bacterial inflammation of the mucous membranes | |
| CN102406126B (en) | Red starter fermented highland barley chewable tablets and preparation method thereof | |
| EP1952703A1 (en) | Product including living probiotic micro organisms | |
| EP1064855B1 (en) | Foods relating to lowering human cholesterol level | |
| WO2002039832A1 (en) | Use of lactitol for improving intestinal microflora | |
| JP2006028051A (en) | Ameliorant for exhausted feeling at time of rising, composition for ameliorating exhausted feeling at time of rising, and food and beverage for ameliorating exhausted feeling at time of rising, containing them | |
| JP6787595B2 (en) | Blood flow improver, royal jelly composition and method for producing royal jelly composition | |
| DE10008279A1 (en) | Synergistic medicinal or health-promoting food additive composition, comprising lactose, inulin and/or oligofructose, calcium salt and Bifidus bacteria, having e.g. immunostimulant and digestion improving action | |
| KR20160070912A (en) | A composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract | |
| JP3807464B2 (en) | Anti-obesity agent | |
| US20170348361A1 (en) | Probiotic augmentation of anti-tumor endothelium immune responses | |
| JP2008074835A (en) | Harmful metal excretion agent, method of using the same, and food supplement | |
| GR1010228B (en) | Orally-administrated nutrition supplement of vitamins, minerals, natural extracts and probiotics for boositng the immune system | |
| JP5035494B2 (en) | Antiallergic composition | |
| US20030165557A1 (en) | Food, medicine and method relating to Bifidobacterium proliferation promoting action, allergy preventive action and human cholesterol lowering action | |
| EP3019037B1 (en) | An oral composition comprising l. rhamnosus gg for use in the prevention and/or treatment of herpes labialis | |
| JP7108992B1 (en) | Composition containing ingredient derived from pericarp of sea buckthorn | |
| JP6537887B2 (en) | Vertigo improving agent | |
| WO2023176952A1 (en) | Composition for controlling proliferation of bacterium in intestine, and use thereof | |
| JP2019107039A (en) | Concentration enhancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2001222369 Country of ref document: AU |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |